Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Ikaros family zinc finger (IKZF) proteins, including IKZF1 (Ikaros), IKZF2 (Helios), IKZF3 (Aiolos), and IKZF4 (Eos), are a group of transcription factors essential for the development and regulation of the immune system. These proteins play critical roles in lymphocyte differentiation and the maintenance of immune homeostasis, particularly in the suppression of effector T-cell functions by regulatory T-cells (Tregs). In the context of oncology, IKZF proteins are often exploited by tumors to maintain an immunosuppressive microenvironment, where high levels of Helios and Eos in Tregs prevent robust anti-tumor immune responses. BMS-986482 is a novel small-molecule Cereblon E3 Ligase Modulator (CELMoD) designed to act as a pan-degrader of the IKZF1-4 family. By inducing the selective degradation of these transcription factors, the drug aims to reprogram the immune environment, reversing Treg-mediated suppression and enhancing the activity of effector T-cells against solid tumors.
Cereblon (CRBN)-dependent proteasomal degradation (CELMoD)
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ikaros family zinc finger proteins 1-4 (IKZF1-4).